AP-PA02
Phase 2- Indications
- Cystic fibrosis, Pseudomonas aeruginosa infections
Company intelligence / Profile preview
Phagelux has more than a dozen phage-based biological products commercially available worldwide for crop science, animal health and food safety. Its human health pipeline includes topical treatments for burns and ulcers targeting antibiotic-resistant bacteria; some of these are at pre-clinical or early clinical stages. The company is recognized as a leader in precision biological agriculture with ongoing R&D into new applications.[1][5]
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Phagelux.